<DOC>
	<DOC>NCT01289210</DOC>
	<brief_summary>This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.</brief_summary>
	<brief_title>VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<criteria>Major low grade B cell lymphoma 1 or more sites of disease appropriate for intratumoral injection measurable disease other than the injection site Performance Status of 1 or better Adequate bone marrow, renal and hepatic function No active autoimmune disease or systemic immunosuppressive drugs Life expectancy &gt; 4 months Known HIV Known brain metastases Malignancy within last 5 yrs (basal cell or noninvasive squamous cell carcinoma OK) Anticoagulation therapy other than 325mg QD ASA Significant cardiovascular disease Pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>B cell</keyword>
	<keyword>lymphoma</keyword>
</DOC>